



Iceland   
Liechtenstein  
Norway grants



# **ENSURE - Educating students for developing high quality research skills**

This material was realised with the EEA Financial Mechanism 2014-2021 financial support. Its content (text, photos, videos) does not reflect the official opinion of the Programme Operator, the National Contact Point and the Financial Mechanism Office. Responsibility for the information and views expressed therein lies entirely with the author(s).

23. October 2019

# Cohort design


---

Finn Egil Skjeldestad  
Institute of community medicine  
UiT The arctic university of Norway  
Tromsø  
Norway

# Cohort study




**Disease-free general population**




Exposure


Yes




No



**Disease**



# Cohort vs. case-control design



# Selection of study population

- General population
- Repetitive populationbased studies
  - \*The Tromsø study (7 repetitions with biobanks), HUNT\* (another populationbased study in Norway)
- Work-related databases
- By residence\*
- Other groups
  - Ethnic groups, religious groups
  - Professional databases
    - Nurses' Health Study
- Public/private insurance databases
- Military/veteran databases

# Measuring exposure



## **T0-baseline – change in exposure from baseline**

Exposure measured for each individual at the beginning of the study and assessed at intervals during the period of follow-up.

## **T0-baseline – change in confounders (co-morbidity)**

**Many cohort studies do only have exposure at baseline**

# Measuring outcome



## Sources for outcome:

- ❖ Medical records
- ❖ Registry data
  - Cancer registry
  - Disease specific quality registers
  - Death certificates
- ❖ **Direct from the participants**

**Validation of outcome**

Method used to ascertain outcome must be identical for both exposed and unexposed participants

# Follow-up



## Passive follow-up through:

- ❖ Medical records
- ❖ Registry data
  - Cancer registry
  - Disease specific quality registers
  - Death certificates

## Active follow-up by visits at interval

- ❖ **Direct from the participants**

- Feasible
- Little costs/merging files

- Time-consuming
- Costly



# Potential sources of bias in cohort studies



- ❖ Lost-to-follow-up (< 5% very good, > 20% not acceptable)
- ❖ Attrition rate (> 95% very good, < 80% not acceptable)
- ❖ Misclassification of **exposure**
  - ❖ Differential misclassification (unexposed are exposed; underestimation of the real effect)
- ❖ Misclassification of **outcome** (over-under-estimation of effect)
- ❖ Missed outcomes (lost-to-follow-up)
- ❖ Healthy worker effect (occupation) – stay healthy – continued participation

Inverse

# Outcome measures – incidence/relative risk

## Smoking and risk for MI

|         | MI + | Person-yrs | Incidence rate/<br>1000 person-yrs |
|---------|------|------------|------------------------------------|
| Smoke + | 84   | 2700       | 31,1                               |
| Smoke - | 87   | 5000       | 17,4                               |

|                    |                          |             |            |
|--------------------|--------------------------|-------------|------------|
| Relative risk (RR) | <u>Incidence exposed</u> | <u>31.1</u> | <u>1.8</u> |
|                    | Incidence unexposed      | 17.4        |            |

# OR $\approx$ RR when:



- The disease is rare
- The cases are representative of exposure to the disease in the background population
- The controls are representative of exposure to those without disease in the background population



## Number needed to treat:

- ❖ Prospective studies measure incidence differences
- ❖ Provide information for assessing how many persons who need to be treated to prevent one case from the «outcome»

NNT – number needed to treat  
= 1/absolute decrease in risk

NNH – number needed to harm  
= 1/absolute increase in risk

When treating atrial flutter with warfarin, the incidence of cerebral infarction are reduced from 5.1% to 1.8%. In order to prevent one case of cerebral infarction you need to treat...

$$\text{NNT} = 1 / (0.051 - 0.018) = 1 / (0.033) = 33.3$$

# Weaknesses of cohort studies



- Costly and time consuming – sample size – long follow-up time.
- Prone to bias due to loss to follow-up.
- Prone to confounding.
- Participants may move between one exposure category – multiple f-up
- Knowledge of exposure status may bias classification of the outcome
- Being in the study may alter participant's behaviour.
- Classification of individuals (exposure or outcome status) can be affected by changes in diagnostic procedures
- Poor choice for the study of a **rare disease**

# Strengths of cohort studies



- Can measure incidence and prevalence
- Exposure is measured before the onset of disease (in prospective cohort studies, measurement of exposure is unrelated to disease)
- Demonstrate direction of causality
- Multiple outcomes can be measured for any one exposure
- Good for measuring **rare exposures**, for example among different occupations